Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
Exicure (Nasdaq: XCUR) has received an extension from the Nasdaq Hearings Panel to continue its listing on The Nasdaq Capital Market. The company must demonstrate compliance with all applicable criteria by November 14, 2024. Exicure is actively working to meet the Panel's requirements and maintain its Nasdaq listing. The company has already regained compliance with Nasdaq's minimum bid price requirement and has exchanged approximately $1,000,000 of debt for equity at a conversion price of $3.00 per share.
Exicure (Nasdaq: XCUR) ha ricevuto un'estensione dal Nasdaq Hearings Panel per continuare la sua quotazione sul Nasdaq Capital Market. L'azienda deve dimostrare di essere conforme a tutti i criteri applicabili entro il 14 novembre 2024. Exicure sta lavorando attivamente per soddisfare i requisiti del Panel e mantenere la sua quotazione su Nasdaq. L'azienda ha già riacquistato la conformità con il requisito del prezzo minimo di offerta di Nasdaq e ha scambiato circa 1.000.000 di dollari di debito per equity a un prezzo di conversione di 3,00 dollari per azione.
Exicure (Nasdaq: XCUR) ha recibido una extensión del Nasdaq Hearings Panel para continuar su cotización en el Nasdaq Capital Market. La compañía debe demostrar el cumplimiento de todos los criterios aplicables antes del 14 de noviembre de 2024. Exicure está trabajando activamente para cumplir con los requisitos del Panel y mantener su cotización en Nasdaq. La empresa ya ha recuperado el cumplimiento del requisito del precio mínimo de oferta de Nasdaq y ha intercambiado aproximadamente 1.000.000 de dólares de deuda por capital a un precio de conversión de 3,00 dólares por acción.
엑시큐어(나스닥: XCUR)는 나스닥 심의 위원회로부터 나스닥 자본 시장에서의 상장을 계속할 수 있도록 연장을 받았습니다. 이 회사는 모든 적용 가능한 기준을 2024년 11월 14일까지 준수해야 합니다. 엑시큐어는 위원회의 요구 사항을 충족하고 나스닥 상장을 유지하기 위해 적극적으로 노력하고 있습니다. 이 회사는 이미 나스닥의 최소 입찰 가격 요구 사항을 충족했으며 약 1,000,000 달러의 부채를 주식으로 교환했습니다. 전환 가격은 주당 3.00달러입니다.
Exicure (Nasdaq: XCUR) a reçu une prolongation du Nasdaq Hearings Panel pour continuer sa cotation sur le Nasdaq Capital Market. La société doit démontrer sa conformité avec tous les critères applicables d'ici le 14 novembre 2024. Exicure travaille activement à remplir les exigences du Panel et à maintenir sa cotation sur Nasdaq. L'entreprise a déjà retrouvé sa conformité avec l'exigence de prix d'offre minimum du Nasdaq et a échangé environ 1 000 000 $ de dettes contre des actions à un prix de conversion de 3,00 $ par action.
Exicure (Nasdaq: XCUR) hat eine Verlängerung vom Nasdaq Hearings Panel erhalten, um seine Listung am Nasdaq Capital Market fortzusetzen. Das Unternehmen muss bis zum 14. November 2024 die Einhaltung aller geltenden Kriterien nachweisen. Exicure arbeitet aktiv daran, die Anforderungen des Panels zu erfüllen und seine Nasdaq-Listung aufrechtzuerhalten. Das Unternehmen hat bereits die Anforderungen an den Mindestgebotskurs von Nasdaq erfüllt und hat etwa 1.000.000 Dollar Schulden gegen Eigenkapital eingetauscht zu einem Umwandlungspreis von 3,00 Dollar pro Aktie.
- Received extension for continued Nasdaq listing until November 14, 2024
- Regained compliance with Nasdaq's minimum bid price requirement
- Converted $1,000,000 of debt to equity at $3.00 per share
- Risk of potential delisting if compliance criteria are not met by November 14, 2024
As previously announced, the Company has regained compliance with Nasdaq’s minimum bid price requirement and exchanged approximately
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company's common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918066146/en/
Josh Miller
847-673-1700
media@exicuretx.com
Source: Exicure, Inc.
FAQ
What extension did Exicure (XCUR) receive from Nasdaq on September 17, 2024?
How much debt did Exicure (XCUR) convert to equity and at what price?
What compliance requirement has Exicure (XCUR) already regained?
By what date must Exicure (XCUR) demonstrate compliance with Nasdaq listing criteria?
